Clinical Trials Logo

Head and Neck Carcinoma clinical trials

View clinical trials related to Head and Neck Carcinoma.

Filter by:

NCT ID: NCT03602079 Completed - Prostate Cancer Clinical Trials

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Start date: July 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

NCT ID: NCT03602066 Terminated - Clinical trials for Head and Neck Carcinoma

Study Evaluating The Role of ClO2 on Mucositis for Pt. Undergoing Head/Neck Radiotherapy

Start date: February 14, 2019
Phase: Phase 2
Study type: Interventional

This pilot randomized phase II trial studies who well chlorine dioxide sterilization works in reducing oral mucositis in patients with stage I-IV head and neck cancer who are undergoing radiotherapy. Chlorine dioxide sterilization may help to treat oral mucositis.

NCT ID: NCT03591666 Not yet recruiting - Adenocarcinoma Clinical Trials

A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

Start date: July 15, 2018
Phase: Phase 2
Study type: Interventional

This is a non-randomized, phase II, open label study of anlotinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.

NCT ID: NCT03556228 Recruiting - Breast Cancer Clinical Trials

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Start date: June 8, 2018
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

NCT ID: NCT03524326 Completed - Clinical trials for Head and Neck Cancer

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Start date: April 30, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people. This study will help find out if lenvatinib and cetuximab is a safe and useful combination for treating patients with HNSCC and cSCC.

NCT ID: NCT03489252 Completed - Clinical trials for Head and Neck Carcinoma

Remote Activity Monitored by Fitbit Charge 3 in Investigating Daily Step and Sleep Data in Participants With Head and Neck Cancer Undergoing Radiation Therapy

Start date: April 20, 2018
Phase: N/A
Study type: Interventional

This pilot trial studies remote activity monitored by Fitbit Charge 3 in investigating daily step and sleep data in participants with head and neck cancer who are undergoing radiation therapy. A wearable remote activity tracking device, such as the Fitbit Charge 3, may help to detect early signs of treatment or disease-related symptoms, improve quality of life, decrease emergency room visits, and decrease hospitalizations in participants with head and neck cancer.

NCT ID: NCT03370276 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Start date: December 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Specifically, investigators want to determine if the combination of Cetuximab and nivolumab can help people with advanced cases of HNSCC. Both cetuximab and nivolumab have been used separately to treat HNSCC and are Food and Drug Administration (FDA) approved in this type of cancer.

NCT ID: NCT03340038 Completed - Clinical trials for Head and Neck Cancer

Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps

ICU
Start date: April 10, 2016
Phase: N/A
Study type: Interventional

Patients undergoing free flap reconstructive surgery at University of California, Davis Medical Center (UCDMC) will be assigned randomly into no intervention group (immediate post operative care in an ICU) or intervention group (immediate post operative care in a non-ICU specialty ward). The investigators hypothesize that there is no significant difference in the length of stay (LOS) or complication rate between head and neck free flaps patients managed immediately post-operatively in an ICU versus a non-ICU specialty ward. The primary objective is to compare the postoperative LOS between head and neck free-flap patients managed initially in an ICU versus a non-ICU specialty ward. The secondary objective is to compare differences in the rate of complications between head and neck free flap patients managed initially in an ICU versus a non-ICU specialty ward. Finally, the tertiary objective is to compare differences in resource utilization between head and neck free-flap patients managed initially in an ICU versus a non-ICU specialty ward.

NCT ID: NCT03268993 Completed - Clinical trials for Head and Neck Cancer

Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer

Start date: July 27, 2018
Phase: N/A
Study type: Interventional

Avmacol is an over-the-counter dietary supplement containing broccoli seed and sprout extracts in tablet form, hypothesized to activate protective cellular pathways including detoxication. In this study, participants who have been curatively treatment for head and neck cancer, will take Avmacol twice a day for 3 months.

NCT ID: NCT03261180 Withdrawn - Clinical trials for Head and Neck Carcinoma

Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer

Start date: November 30, 2017
Phase: N/A
Study type: Interventional

This randomized clinical trial studies how well Nestle Impact Advanced Recovery works in improving surgery recovery in patients with head and neck cancer. Adding a nutritional supplement, such as Nestle Impact Advanced Recovery to a regular diet before and after head and neck cancer surgery may help to decrease the number of wound complications after surgery.